NYSEAMERICAN:ARMP Armata Pharmaceuticals (ARMP) Stock Price, News & Analysis $4.10 +0.03 (+0.74%) Closing price 09/17/2026 04:10 PM EasternExtended Trading$4.17 +0.07 (+1.71%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsNews and TrendsOwnershipSEC FilingsShort Interest About Armata Pharmaceuticals Stock (NYSEAMERICAN:ARMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Armata Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.09▼$4.3250-Day Range$3.76▼$5.8452-Week Range$2.92▼$16.34Volume253,293 shsAverage Volume353,460 shsMarket Capitalization$152.44 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company Overview Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapies for serious bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy specific bacteria. Armata’s approach is intended to address drug-resistant infections while limiting disruption to beneficial bacteria. The company’s pipeline has included inhaled phage products designed to treat chronic respiratory infections caused by Pseudomonas aeruginosa, including infections associated with cystic fibrosis and other structural lung diseases. Armata has also developed phage-based candidates targeting Staphylococcus aureus infections, including serious systemic infections. Its work includes phage discovery, selection and engineering, formulation, and the clinical development of pathogen-specific treatments. Armata is based in Marina del Rey, California, and serves the biotechnology and healthcare markets through research and clinical development activities. The company was formerly known as Synthetic Biologics, Inc. and adopted the Armata Pharmaceuticals name as it concentrated its operations on bacteriophage therapeutics. Because its products remain in development, their availability and approved uses depend on the results of clinical trials and regulatory review.AI Generated. May Contain Errors. Read More Armata Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreARMP MarketRank™: Armata Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingArmata Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialArmata Pharmaceuticals has a consensus price target of $15.00, representing about 265.9% upside from its current price of $4.10.Amount of Analyst CoverageArmata Pharmaceuticals has received no research coverage in the past 90 days.Read more about Armata Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Armata Pharmaceuticals are expected to decrease in the coming year, from $0.50 to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Armata Pharmaceuticals is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Armata Pharmaceuticals is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Armata Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.36% of the float of Armata Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArmata Pharmaceuticals has a short interest ratio ("days to cover") of 8.68.Change versus previous monthShort interest in Armata Pharmaceuticals has recently increased by 6.06%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArmata Pharmaceuticals does not currently pay a dividend.Dividend GrowthArmata Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentArmata Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Armata Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ARMP on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Armata Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Armata Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders84.50% of the stock of Armata Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions3.57% of the stock of Armata Pharmaceuticals is held by institutions.Read more about Armata Pharmaceuticals' insider trading history. Receive ARMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Armata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARMP Stock News HeadlinesArmata Wins FDA Breakthrough Therapy Designation For AP-SA02 In Complicated SAB; Stock UpSeptember 14, 2026 | rttnews.comArmata Pharmaceuticals' AP-SA02 Gets FDA Breakthrough Therapy DesignationSeptember 14, 2026 | marketscreener.comMIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved. | Banyan Hill Publishing (Ad)Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial TreatmentSeptember 14, 2026 | marketscreener.comMArmata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02September 14, 2026 | prnewswire.comArmata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | prnewswire.comArmata Pharmaceuticals Advances Phage Therapy Research With New Ar-KM PublicationSeptember 3, 2026 | rttnews.comArmata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation AntibacterialsSeptember 3, 2026 | prnewswire.comSee More Headlines ARMP Stock Analysis - Frequently Asked Questions How have ARMP shares performed this year? Armata Pharmaceuticals' stock was trading at $6.28 at the beginning of the year. Since then, ARMP shares have decreased by 34.7% and is now trading at $4.10. How were Armata Pharmaceuticals' earnings last quarter? Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) released its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.18. The firm earned $2.51 million during the quarter, compared to analyst estimates of $0.40 million. Armata Pharmaceuticals had a negative trailing twelve-month return on equity of 12.24% and a negative net margin of 3,467.04%. Who are Armata Pharmaceuticals' major shareholders? Armata Pharmaceuticals' top institutional investors include Madison Asset Management LLC (5.74%), BlackRock Inc. (1.53%), Bank of New York Mellon Corp (0.08%) and Deutsche Bank AG (0.03%). View institutional ownership trends. How do I buy shares of Armata Pharmaceuticals? Shares of ARMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Armata Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Armata Pharmaceuticals investors own include VBI Vaccines (VBIV), Altimmune (ALT), Pfizer (PFE), Advanced Micro Devices (AMD), Co-Diagnostics (CODX) and Amarin (AMRN). Company Calendar Last Earnings8/12/2026Today9/18/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ARMP's financial health is in the Yellow zone, according to TradeSmith. ARMP has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:ARMP CIK921114 Webwww.armatapharma.com Phone(310) 655-2928Fax310-665-2963Employees61Year FoundedN/APrice Target and Rating Average Price Target for Armata Pharmaceuticals$15.00 High Price Target$15.00 Low Price Target$15.00 Potential Upside/Downside+265.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E Ratio8.20 P/E GrowthN/ANet Income-$173.80 million Net Margins-3,467.04% Pretax Margin-3,467.04% Return on Equity-12.24% Return on Assets32.16% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$4.90 million Price / Sales31.11 Cash FlowN/A Price / Cash FlowN/A Book Value($6.00) per share Price / Book-0.68Miscellaneous Outstanding Shares37,180,000Free Float5,763,000Market Cap$152.44 million OptionableNot Optionable Beta1.34 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSEAMERICAN:ARMP) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Armata Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARMP Stock Alerts